Equities research analysts forecast that Mesoblast limited (NASDAQ:MESO) will post ($0.24) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Mesoblast’s earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.22). Mesoblast posted earnings per share of ($0.22) in the same quarter last year, which suggests a negative year over year growth rate of 9.1%. The company is expected to issue its next earnings results on Wednesday, September 4th.
According to Zacks, analysts expect that Mesoblast will report full-year earnings of ($0.93) per share for the current financial year, with EPS estimates ranging from ($1.00) to ($0.82). For the next year, analysts expect that the firm will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.08) to ($0.85). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Mesoblast.
Mesoblast (NASDAQ:MESO) last announced its quarterly earnings results on Thursday, May 30th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). The firm had revenue of $1.25 million during the quarter, compared to the consensus estimate of $1.23 million. Mesoblast had a negative return on equity of 17.13% and a negative net margin of 546.34%.
Shares of Mesoblast stock remained flat at $$4.95 during trading hours on Wednesday. The stock had a trading volume of 10 shares, compared to its average volume of 30,263. The stock has a fifty day moving average of $5.09 and a 200 day moving average of $5.03. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.92 and a current ratio of 1.92. The stock has a market cap of $449.20 million, a P/E ratio of -7.86 and a beta of 1.84. Mesoblast has a 12 month low of $3.35 and a 12 month high of $8.78.
A hedge fund recently raised its stake in Mesoblast stock. Morgan Stanley boosted its position in Mesoblast limited (NASDAQ:MESO) by 284.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,702 shares of the company’s stock after purchasing an additional 109,295 shares during the period. Morgan Stanley owned about 0.16% of Mesoblast worth $784,000 as of its most recent SEC filing. 2.71% of the stock is currently owned by institutional investors.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.